publication . Article . 2012

Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands

Piening, Sigrid; Haaijer-Ruskamp, Flora M.; de Graeff, Pieter A.; Straus, Sabine M. J. M.; Mol, Peter G. M.;
Open Access English
  • Published: 01 Jan 2012
Background: In Europe, Direct Healthcare Professional Communications (DHPCs) are important tools to inform healthcare professionals of serious, new drug safety issues. However, this tool has not always been successful in effectively communicating the desired actions to healthcare professionals. Objective: The aim of this study was to explore healthcare providers' experiences and their preferences for improvement of risk communication, comparing views of general practitioners (GPs), internists, community pharmacists and hospital pharmacists. Methods: A questionnaire was developed and pilot tested to assess experiences and preferences of Dutch healthcare professio...
Medical Subject Headings: educationhealth care economics and organizations
Download from
29 references, page 1 of 2

1. Stricker BC, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004 07; 329 (7456): 44-7

2. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. J Am Med Assoc 2008 10; 300 (16): 1887-96

3. Arnardottir AH, Haaijer-Ruskamp FM, Straus SMJ, et al. Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol 2011; 72 (3): 490-9 [OpenAIRE]

4. Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 2001; 10 (3): 211-8

5. Guo JJ, Curkendall S, Jones JK, et al. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12 (4): 295-301

6. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164 (9): 1356-63

7. Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65 (1): 94-101

8. Valuck RJ, Libby AM, Orton HD, et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007; 164 (8): 1198-205 [OpenAIRE]

9. European Commission. Volume 9A of the rules governing medicinal products in the European Union. Guidelines on pharmacovigilance for medicinal products for human use. 2008 Sep [online]. Available from URL: http://ec.europa. eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf [Accessed 2012 Feb 13]

10. Slovic P. Perceived risk, trust, and democracy. Risk Anal 1993; 13 (6): 675-82

11. The European Parliament and The European Council. REGULATION (EU) No 1235/2010. 2010 [online]. Available from URL: [Accessed 2012 Feb 13]

12. The European Parliament and The European Council. DIRECTIVE 2010/84/EU. 2010 [online]. Available from URL: OJ:L:2010:348:0074:0099:EN:PDF [Accessed 2012 Feb 13]

13. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 2003 10; 362 (9391): 1225-30

14. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. J Am Med Assoc 1999 10; 282 (15): 1458-65 [OpenAIRE]

15. Dutch Medicines Evaluation Board. Direct Healthcare Professional Communications (DHPCS). 2012 [online]. Available from URL: human-medicines/pharmacovigilance/DHPC/default.htm [Accessed 2012 Feb 10]

29 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue